| Excerpt | Reference |
|---|
| "41 children with juvenile rheumatoid arthritis (JRA) and 6 with postinfectious arthropathies, aged 3--15 years, were treated with acetylsalicylic acid for 14 days during which time the patients were hospitalized." | ( Mäkela, AL; Mattila, M; Yrjänä, T, 1979) |
| "The three principal syndromes of juvenile rheumatoid arthritis have distinctive features that aid in early diagnosis and can contribute to specificity of treatment." | ( Schaller, JG; Wedgwood, RJ, 1977) |
| "In a case of juvenile rheumatoid arthritis with large synovial cysts, cyst fluid aspiration was performed to relieve pain, but recurrence was prevented with salicylate therapy alone." | ( Bamzai, A; Kretschmer, RR; Krieger, M, 1978) |
| "Two 19 year old patients with juvenile chronic arthritis developed liver toxicity during treatment with sulphasalazine." | ( Caspi, D; Fuchs, D; Yaron, M, 1992) |
| "The goals of pharmacotherapy in juvenile rheumatoid arthritis (JRA) are to suppress chronic synovitis which causes potential cartilage destruction and deformities, to control the systemic effects of inflammation (including growth retardation and nutritional deficits), relieve pain and limit psychological impact of disease." | ( Doughty, RA; Rose, CD, 1992) |
| "Among 664 juvenile chronic arthritis patients cared for in the Outpatient Clinic of the Pediatric Rheumatology Unit of the National Institute of Rheumatology and Physiotherapy 11 were found with juvenile psoriatic arthritis, and their data regarding skin, joint, ophthalmological, laboratory and radiological manifestations were analysed." | ( Balogh, Z; Gömör, B; Koó, E, 1991) |
| "Ninety-two children with juvenile rheumatoid arthritis were randomly assigned to treatment in a multicenter, double-blind, 12-week trial designed to compare the efficacy and safety of a liquid formulation of ibuprofen at a dosage of 30 to 40 mg/kg/day versus those of aspirin at a dosage of 60 to 80 mg/kg/day." | ( Bernstein, B; Brewer, EJ; Fink, CW; Giannini, EH; Gibbas, D; Hoyeraal, HM; Miller, ML; Passo, MH; Person, DA; Sawyer, LA, 1990) |
| "Twenty-nine children with juvenile rheumatoid arthritis were studied to determine the safety and efficacy of methotrexate therapy." | ( Athreya, BH; Eichenfield, AH; Goldsmith, DP; Rose, CD; Singsen, BH, 1990) |
| "An 8-year-old black girl with juvenile rheumatoid arthritis, who had been treated with intramuscular injections of gold salts, had a Ga-67 study as part of her workup." | ( Bekerman, C; Moult, RG, 1989) |
| "A 4-year-old female patient with juvenile rheumatoid arthritis received a mucosal burn from chewable-aspirin therapy." | ( Maron, FS, 1989) |
| "Two of the patients had untreated juvenile chronic arthritis, three had a pyogenic joint infection, four had Henoch-Schonlein purpura and eight had reactive arthropathy." | ( Bunger, E; Fogh, K; Herlin, T; Storm, K; Ternowitz, T, 1987) |
| "Sixty-two patients with juvenile chronic arthritis (JCA) were randomized to 50-week treatment with either sodium aurothiomalate (G) or D-penicillamine (PEN) and followed with regard to radiographic changes of the temporomandibular joints (TMJ)." | ( Høyeraal, HM; Kvien, TK; Larheim, TA; Sandstad, B, 1986) |
| "The monocytes from patients with juvenile rheumatoid arthritis receiving no anti-erosive therapy (n = 10) degraded significantly more bone than did cells obtained from normal controls (n = 10, P less than 0." | ( Anast, CS; Beyer, E; Cairns, L; Carnes, D; Hoch, S; Key, LL, 1986) |
| "Thirty-four patients with juvenile rheumatoid arthritis, who were treated with flurbiprofen at a maximum dose of 4 mg/kg/day, had statistically significant decreases from baseline in 6 arthritis indices after 12 weeks of treatment." | ( Athreya, B; Bass, J; Brandstrup, N; Brewer, E; Di Ianni, M; Goldsmith, D; Hollister, R; Kredich, D; Miller, J, 1986) |
| "Children suffering from juvenile chronic arthritis need a longterm therapy and guidance for many years, in course of which drug therapy is only one part of the whole treatment regimen." | ( Tulzer, W, 1987) |
| "Children suffering from juvenile chronic arthritis need a longterm therapy and guidance for many years." | ( Tulzer, W, 1985) |
| "Thirty five patients with juvenile chronic arthritis who had not been treated with cytotoxic drugs served as controls." | ( Ansell, BM; Denman, AM; Doré, CJ; Palmer, RG; Varonos, S, 1985) |
| "A 4-year-old girl with juvenile rheumatoid arthritis developed fever, protracted vomiting, disturbance of consciousness and decorticate posture following the administration of salicylate." | ( Horikoshi, T; Okada, S; Yamashita, F; Yoshida, I, 1984) |
| "Pharmacotherapy of juvenile rheumatoid arthritis should always be individualized." | ( Lindsley, CB, 1981) |
| "A revision of the treatment of the juvenile chronic arthritis (JCA) is made, Salicylates, still in use, require control of the salicylate level in order to obtain a higher efficiency and to prevent toxicity." | ( Casado de Frías, E; Elosegui, J; López-Ibor, B; Miranda, M; Valverde Moreno, F; Vázquez, L, 1981) |
| "Drug therapy of juvenile rheumatoid arthritis is discussed." | ( Suschke, HJ, 1980) |
| "New information on the treatment of juvenile rheumatoid arthritis emphasizes more aggressive control of arthritis, particularly the use of methotrexate, both in low- and higher-dose regimens." | ( Emery, HM, 1993) |
| "Intraarticular steroid therapy in juvenile chronic arthritis (JCA) is performed because of high local efficacy with few side effects." | ( Eich, GF; Hallé, F; Hodler, J; Seger, R; Willi, UV, 1994) |
| "To distinguish the effects of juvenile rheumatoid arthritis (JRA) on bone mineralisation from those possibly caused by steroid therapy." | ( Alessio, M; Iaccarino, E; Iammarrone, CS; Marotta, A; Pirozzi, M; Polito, C; Rea, L; Strano, CG; Todisco, N, 1995) |
| "The treatment of juvenile chronic arthritis relies on drugs, but not exclusively." | ( Prieur, AM, 1994) |
| "In three patients with juvenile rheumatoid arthritis, serum IgA concentrations were within the normal limit at the onset of disease and before aspirin administration." | ( Kondo, N; Orii, T; Takao, A, 1993) |
| "A 12-year-old girl with juvenile chronic arthritis was treated with cyclosporine A for recurrent uveitis." | ( Lee, FD; Morris, AJ; Murphy, EA; Sturrock, RD; Walker, E, 1993) |
| "Thirteen juvenile chronic arthritis patients with abdominal symptoms related to non-steroidal anti-inflammatory drug therapy were endoscoped before and after a 6-week course of either misoprostol or ranitidine therapy." | ( Hayllar, J; Hermaszewski, R; Woo, P, 1993) |
| "In a cohort of children with juvenile rheumatoid arthritis treated with nonsteroidal antiinflammatory drugs and referred for gastrointestinal complaints, more than 75% had gastritis, antral erosions, or ulcers." | ( Bern, E; Grand, RJ; Linz, C; Mulberg, AE; Tucker, L; Verhave, M, 1993) |
| "Four children with chronic arthritis (3 juvenile rheumatoid arthritis and 1 juvenile ankylosing spondylitis) and poorly controlled chronic uveitis, were given sulphasalazine (SASP) therapy for a mean period of 3." | ( Hsieh, KH; Huang, JL; Hung, IJ, 1997) |
| "The goal of treatment for juvenile rheumatoid arthritis (JRA) and other pediatric rheumatic disorders is to minimize joint destruction, pain, and deformity and to maximize all aspects of growth and development." | ( Goldbach-Mansky, R; Singsen, BH, 1997) |
| "Children with juvenile rheumatoid arthritis (JRA) treated with methotrexate (MTX) were examined for their course after the discontinuation of the drug to define the relapse and remission rates and to identify predictors of relapse." | ( Gottlieb, BS; Ilowite, NT; Keenan, GF; Lu, T, 1997) |
| "Studied children with mild to moderate juvenile rheumatoid arthritis who were massaged by their parents 15 minutes a day for 30 days (and a control group engaged in relaxation therapy)." | ( Field, T; Hernandez-Reif, M; Krasnegor, J; Kuhn, C; Rivas-Chacon, R; Schanberg, S; Seligman, S; Sunshine, W, 1997) |
| "A 12-year-old girl with juvenile rheumatoid arthritis developed fulminant hepatic failure, thrombocytopenia and erythroid hypoplasia, which was confirmed by liver histology and bone marrow examination, 2 weeks after initiation of sulphasalazine therapy." | ( Chen, LC; Hsieh, KH; Hsueh, C; Huang, JL; Hung, IJ; Lee, WY, 1998) |
| "Thirty-two children affected by juvenile rheumatoid arthritis (JRA) were studied with serial measurements of bone mass for an average of 18 months, to evaluate the effects of long-term methotrexate (MTX) treatment on bone." | ( Bardare, M; Bianchi, ML; Cherubini, R; Cimaz, R; Corona, F; Galbiati, E, 1999) |
| "Its application for juvenile chronic arthritis (JCA) is limited so far and controversial results for the efficacy of this therapy have been published." | ( Dyankov, ED; Varbanova, BB, 1999) |
| "Seven children with active juvenile idiopathic arthritis refractory to at least combination therapy with methotrexate and sulfasalazine or cyclosporin A were studied." | ( Burdach, S; Horneff, G; John, V; Keysser, G; Mathony, K; Schmeling, H, 2001) |
| "A 15-year-old boy with refractory juvenile rheumatoid arthritis (JRA) underwent intense immunosuppressive therapy followed by purified blood CD34+ cell autografting." | ( Kanamaru, S; Kawano, Y; Kuroda, Y; Matsuoka, S; Nakagawa, R; Nakayama, H; Onishi, T; Suzuya, H; Watanabe, T; Yamashita, K; Yoshimura, E, 2001) |
| "Early diagnosis of juvenile idiopathic arthritis (JIA) facilitates earlier more aggressive therapy, and improved outcome." | ( Gardner-Medwin, JM; Haigh, F; Johnson, K; Ryder, C; Wittkop, B, 2002) |
| "Methotrexate was introduced in the treatment of juvenile idiopathic arthritis (JIA) about fifteen years ago." | ( Malcić, I; Prohić, A; Tambić-Bukovac, L, 2002) |
| "Patients with refractory juvenile idiopathic arthritis can benefit from aggressive therapy." | ( de Castro, TC; Hilário, MO; Len, C; Terreri, MT, 2003) |
| "To describe the outcome of patients with juvenile idiopathic arthritis (JIA) treated with subcutaneous (Sc) methotrexate (MTX) after failing oral MTX (either because of inefficacy or toxicity) in a clinic population." | ( Alsufyani, K; Cabral, DA; Malleson, PN; Ortiz-Alvarez, O; Petty, RE; Tucker, LB, 2004) |
| "The treatment of juvenile idiopathic arthritis has changed a great deal in the last few years." | ( Huppertz, HI; Weller, F, 2005) |
| "The treatment of juvenile idiopathic arthritis (JIA) has changed markedly in the last 15 years." | ( Hashkes, PJ; Laxer, RM, 2005) |
| "Many exciting developments in the treatment of juvenile idiopathic arthritis (JIA) have emerged recently, including new tools to assess the results of clinical trials (eg, the definition of remission and a radiologic scoring tool)." | ( Hashkes, PJ; Laxer, RM, 2006) |
| "Since a proportion of systemic-onset juvenile idiopathic arthritis (SOJIA) patients continue to require long-term corticosteroid therapy for disease control, an effective and safe therapeutic strategy for controlling the activity of refractory SOJIA remains to be established." | ( Ito, E; Kimura, S; Nonaka, K; Oki, ES; Suzuki, K; Tanaka, H; Tsugawa, K, 2007) |
| "Thirty seven children with juvenile idiopathic arthritis (JIA) who were treated with one or more intra-articular triamcinolone acetonide (TA) injections were evaluated." | ( Makay, B; Unsal, E, 2008) |
| "Thirteen children with juvenile idiopathic arthritis (JIA) were treated with intraarticular steroid injection of triamcilone acetonide as a day care procedure." | ( Gupta, R; Kabra, SK; Lodha, R; Verma, S, 2009) |
| "Methotrexate (MTX) is the mainstay treatment for juvenile idiopathic arthritis (JIA), however approximately 30% of children will fail to respond to the drug." | ( Glass, DN; Hinks, A; Kassoumeri, L; Lal, S; Martin, P; Moncrieffe, H; Thompson, SD; Thomson, W; Ursu, S; Wedderburn, LR; Weiler, T, 2011) |
| "In this case report, we present a juvenile rheumatoid arthritis patient whose liver enzymes raised while he was under treatment and afterwards HBV reactivation was determined as the cause." | ( Acar, A; Cakar, E; Carli, AB; Dincer, U; Durmus, O; Kiralp, MZ; Tekin, L; Ulcay, A, 2013) |
| "Treatment of juvenile idiopathic arthritis (JIA) with disease-modifying antirheumatic drugs (DMARDs) may improve outcomes compared to conventional therapy (e." | ( Coeytaux, RR; Kemper, AR; Sanders, GD; Van Mater, HA; Williams, JW, 2012) |
| "Inclusion criteria were diagnosis of juvenile idiopathic arthritis, MTX treatment for at least 6 months, a consistent route of administration of MTX, and no previous or concomitant treatment with biologic agents." | ( Foeldvari, I; Ganser, G; Horneff, G; Kaul, I; Klein, A; Urban, A, 2012) |
| "We report on a 24-year-old woman with juvenile idiopathic arthritis (JIA) who developed subacute thyroiditis (SAT) while being treated with etanercept." | ( Yasuji, I, 2013) |
| "Polyarticular juvenile idiopathic arthritis (JIA) is a category of JIA where multiple joints are affected by chronic inflammation, and where serious and lasting damage to joints is the expected natural history in untreated disease." | ( Baildam, E, 2012) |
| "Methotrexate, the mainstay of treatment in Juvenile idiopathic arthritis, might not be effective in a few patients of polyarticular and systemic onset juvenile idiopathic arthritis." | ( Dewan, V; Jahan, A; Yadav, TP, 2012) |
| "Systemic juvenile idiopathic arthritis (JIA) is the most severe subtype of JIA; treatment options are limited." | ( Baildam, E; Brunner, HI; Burgos-Vargas, R; Calvo, I; Cuttica, R; De Benedetti, F; Dolezalova, P; Garay, SM; Grom, A; Joos, R; Kenwright, A; Lovell, D; Martini, A; Merino, R; Ravelli, A; Ruperto, N; Schneider, R; Woo, P; Wouters, C; Wright, S; Wulffraat, N; Xavier, R; Zemel, L; Zuber, Z; Zulian, F, 2012) |
| "Before the biologic era, treatment of juvenile idiopathic arthritis (JIA) was often highly unsatisfactory, with children forced to endure the ill effects of lifelong disease, including pain and stiffness, disability, and even increased risk of mortality." | ( Cron, RQ; Stoll, ML, 2013) |
| "However, systemic onset juvenile idiopathic arthritis patients receiving MTX must be periodically examined for the development of lymphoproliferative disorder especially if the disease is difficult to control or patient develop new symptoms on therapy." | ( Antony, PT; Basu, D; Negi, VS; Singh, BK; Verma, SK, 2014) |
| "Methotrexate (MTX) is the key treatment in juvenile idiopathic arthritis (JIA)." | ( Ćalasan, MB; Wulffraat, NM, 2014) |
| "Methotrexate, a drug commonly used to treat juvenile idiopathic arthritis (JIA), has been reported to cause interstitial pneumonitis as a rare complication in adults with rheumatoid arthritis." | ( Huang, JL; Liu, YC; Tu, YL; Wu, RC; Yao, TC, 2014) |
| "To follow children with juvenile idiopathic arthritis (JIA) who had completed at least 6 months of the TRial of Early Aggressive Therapy (TREAT) clinical study for an additional 2 years, describing safety of early aggressive treatment, disease activity, function, and duration of clinical inactive disease (CID) during followup." | ( Bohnsack, J; Brunner, HI; Gottlieb, BS; Hendrickson, A; Higgins, GC; Hsu, J; Kimura, Y; Milojevic, D; O'Neil, KM; Punaro, MG; Ringold, S; Schanberg, LE; Spalding, SJ; Wallace, CA, 2014) |
| "For children with juvenile idiopathic arthritis (JIA) who fail to respond to methotrexate, the delay in identifying the optimal treatment at an early stage of disease can lead to long-term joint damage." | ( Decorti, G; Favretto, D; Lepore, L; Malusà, N; Moressa, V; Pastore, S; Stocco, G; Ventura, A; Zandonà, L, 2015) |
| "Children and young people (CYP) with juvenile idiopathic arthritis (JIA) are known to have impaired health-related quality of life (HRQoL), which is improved significantly for many by treatment with methotrexate (MTX)." | ( Mulligan, K; Newman, S; Wedderburn, LR, 2015) |
| "Sixteen eyes with Juvenile idiopathic arthritis (JIA)-associated uveitis received intravitreal dexamethasone implant to treat recalcitrant anterior segment inflammation (43." | ( Baynes, K; Lowder, CY; Nucci, P; Pichi, F; Srivastava, SK, 2017) |
| "Potential long-term side effects of treatment for juvenile idiopathic arthritis are concerning." | ( Avenarius, DF; de Horatio, LT; Hemke, R; Maas, M; Malattia, C; Müller, LS; Nusman, CM; Rieter, JF; Rosendahl, K; van Rossum, MA, 2016) |
| "Fifteen children with suspected juvenile idiopathic arthritis underwent a total of 16 MRI examinations following administration of 10 mg of oral melatonin; satisfactory images were obtained in all but one case, with no adverse events." | ( Bahtijarević, Z; Dukarić, N; Gagro, A; Marjanović, J; Pasini, AM; Roić, G; Tripalo Batoš, A, 2018) |
| "Around one-third of patients with juvenile idiopathic arthritis (JIA) fail to respond to first-line methotrexate (MTX) or anti-tumor necrosis factor (TNF) therapy, with even fewer achieving ≥ American College of Rheumatology Pediatric 70% criteria for response (ACRpedi70), though individual responses cannot yet be accurately predicted." | ( Anink, J; Dolman, KM; Foell, D; Frosch, M; Gohar, F; Holzinger, D; Hoppenreijs, EPAH; Horneff, G; Moncrieffe, H; Prince, FHM; Ten Cate, R; Ursu, S; van Rossum, MAJ; Van Suijlekom-Smit, LWA; Wedderburn, LR, 2018) |
| "Patients with juvenile idiopathic arthritis (JIA) beginning treatment with MTX were prospectively observed in the national JIA biologic register Biologika in der Kinderrheumatologie/Biologics in Paediatric Rheumatology and its follow-up register Juvenile arthritis Methotrexate/Biologics long-term Observation." | ( Horneff, G; Klotsche, J; Minden, K; Niewerth, M, 2018) |
| "FiRst-Line Options for Systemic juvenile idiopathic arthritis Treatment (FROST) is a multicenter, prospective, non-randomized study that compares four Childhood Arthritis and Rheumatology Research Alliance (CARRA) consensus treatment plans for new-onset systemic juvenile idiopathic arthritis: (1) glucocorticoids alone, (2) methotrexate, (3) interleukin-1 blockade, and (4) interleukin-6 blockade." | ( Beukelman, T; Feldman, BM; Kimura, Y; Nigrovic, PA; Schanberg, LE; Tomlinson, G, 2018) |
| "FiRst-Line Options for Systemic juvenile idiopathic arthritis Treatment (FROST) began enrollment in November 2016." | ( Beukelman, T; Feldman, BM; Kimura, Y; Nigrovic, PA; Schanberg, LE; Tomlinson, G, 2018) |
| "FiRst-Line Options for Systemic juvenile idiopathic arthritis Treatment (FROST) will provide the first prospective comparison of Childhood Arthritis and Rheumatology Research Alliance's (CARRA's) consensus-derived non-biologic versus biologic management strategies in systemic juvenile idiopathic arthritis, performed in a real-world setting wherein each patient receives standard-of-care treatment selected by the treating physician." | ( Beukelman, T; Feldman, BM; Kimura, Y; Nigrovic, PA; Schanberg, LE; Tomlinson, G, 2018) |
| "In polyarticular juvenile idiopathic arthritis, methotrexate (MTX) is still used as first-line treatment." | ( Klein, A, 2019) |
| "Early diagnosis and treatment of juvenile idiopathic arthritis (JIA) with conventional and biologic disease-modifying anti-rheumatic drugs have vastly improved outcomes for children with these diseases." | ( Halyabar, O; Horton, DB; Mehta, J; Ringold, S; Rumsey, DG, 2019) |
| "The response to treatment for juvenile idiopathic arthritis (JIA) can be staged using clinical features." | ( Hennon, T; Jarvis, JN; Jiang, K; Li, L; Meng, H; Poppenberg, KE; Sun, Y; Wallace, CA, 2019) |
| "Children with juvenile idiopathic arthritis (JIA) may be predisposed to serious pneumonia due to modern disease-modifying anti-rheumatic treatment." | ( Helminen, M; Kauppi, MJ; Linna, M; Säilä, H; Salonen, JH; Salonen, PH, 2020) |
| "Twenty-three patients with juvenile idiopathic arthritis, already treated with subcutaneous methotrexate in the form of prefilled syringe in the period October 2018 - April 2019 completed a questionnaire evaluating their experience with this device." | ( Roszkiewicz, J; Smolewska, E; Swacha, Z, 2020) |
| "Remission is the primary objective of treating juvenile idiopathic arthritis (JIA)." | ( Alexeeva, E; Alshevskaya, A; Balykova, L; Denisova, R; Dvoryakovskaya, T; Horneff, G; Kriulin, I; Malievskiy, V; Moskalev, A; Nikishina, I; Santalova, G; Spivakovskiy, Y; Stadler, E; Zholobova, E, 2021) |
| "To determine uveitis incidence in juvenile idiopathic arthritis (JIA) patients treated with disease-modifying antirheumatic drugs (DMARD) medications, and to evaluate uveitis risk-stratification protocols." | ( Bison, HS; Bohnsack, BL; Gao, HM; Janetos, TM; Song, J; Zhang, DL, 2023) |
| "The goal of juvenile idiopathic arthritis (JIA) treatment is to maintain clinical remission." | ( Boteanu, A; García-Fernández, A; Garulo, DC; Monteagudo-Saéz, I; Navarro, PG; Nieto-González, JC; Robledillo, JCL; Trives-Folguera, L, 2023) |